Ask Warren

Medy-Tox

086900 · KOSDAQ · ₩086900 · 메디톡스

₩65,800▼ ₩1,700 (2.52%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −46.46%
Market cap
₩480B
Enterprise value
₩555B
P/E
31.3×
P/B
1.3×
Dividend yield
1.8%
ROE
4.1%
Net margin
6.1%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−53.4% from the high

₩61,600Today: ₩65,600 – ₩68,100₩141,100

Returns

  • 1W−4.2%
  • 1M−4.2%
  • 3M−3.5%
  • 6M−39.4%
  • YTD−45.5%
  • 1Y−46.5%
Volume today
13,648
0.9× the 20-day average
Traded today
₩903M
Listed shares
7,298,497
EPS (12 months)
₩2,099
Earnings yield 3.2%
SellBuy
AI research · Update noteMedy-Tox: Model Fair Value Estimate Cut by About a Third to ₩34,974 Base CaseThe update is about the model, not about new company news.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

41Quiet
  • BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Conference presentation of its technology is mildly positive; the dividend filing is routine. Community: 0 bullish, 0 bearish posts this week.
  • MomentumFlat-2.4% over the last month; the price is below its 20-day average.
  • News impactLow5 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Aug 10: buy ₩1.1B at the close (65.2% of 20-day average trading value)

Jul 20Last 15 trading days (% of average trading value)Aug 10

On its 13 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 8.7% of trading value and pointed the same way 1 of 13 times.

  • 2× KODEX KOSDAQ150 Leverage ₩978M
  • 2× TIGER KOSDAQ150 Leverage ₩62M
  • -1× KODEX KOSDAQ150 Futures Inverse ₩34M
  • 2× RISE KOSDAQ150 Futures Leverage ₩20M
  • -1× TIGER KOSDAQ150 Futures Inverse ₩2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

Medy-Tox stock overview

Medy-Tox (메디톡스, KRX: 086900) is listed on KOSDAQ, in the Biotech & Pharma sector. Medytox is a South Korean biopharmaceutical company that researches, develops, manufactures and sells botulinum toxin type A biologic drugs, with its main product Neuronox (Medytoxin) making up most of its revenue. Its shares closed at ₩65,800 on Oct 28, 2026, down 2.52% on the day, giving it a market value of ₩480B.

Key facts

Market cap
₩480B
Sector
Biotech & Pharma
Latest price change
−2.52%
As of
Oct 28, 2026
Main business
Medytox is a South Korean biopharmaceutical company that researches, develops, manufactures and sells botulinum toxin type A biologic drugs, with its main product Neuronox (Medytoxin) making up most of its revenue.

Quick answers about Medy-Tox

What does Medy-Tox do?
Medytox is a South Korean biopharmaceutical company that researches, develops, manufactures and sells botulinum toxin type A biologic drugs, with its main product Neuronox (Medytoxin) making up most of its revenue. Its products, including botulinum toxin and HA filler products for aesthetic and therapeutic uses, are sold through distributors and joint ventures to customers in Korea and about 30 countries overseas, with production facilities located in Chungju, Chungbuk, Korea.
What is the market cap of Medy-Tox?
The market capitalisation of Medy-Tox was ₩480B at the close on Oct 28, 2026.
Who are the largest shareholders of Medy-Tox?
According to the latest official filings, the largest reported holders are Jeong Hyeon-ho (18.74%, as of Aug 28, 2026); National Pension Service (1.44%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.00%, as of Jul 31, 2026).
When is the next earnings report from Medy-Tox?
Korean companies rarely announce results dates in advance. Based on when Medy-Tox filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
Does the National Pension Service own Medy-Tox?
Yes. The National Pension Service held 1.44% of Medy-Tox shares as of Dec 31, 2025.

Company profile

Medytox is a South Korean biopharmaceutical company that researches, develops, manufactures and sells botulinum toxin type A biologic drugs, with its main product Neuronox (Medytoxin) making up most of its revenue. Its products, including botulinum toxin and HA filler products for aesthetic and therapeutic uses, are sold through distributors and joint ventures to customers in Korea and about 30 countries overseas, with production facilities located in Chungju, Chungbuk, Korea.

Written by AI from the company's latest annual report.

Korean name
메디톡스
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Aesthetics & botox
CEO
정현호
Founded
May 2000
Listed
Jan 2009
Listed shares
7,298,497
Fiscal year ends
Month 12
Website
www.medytox.com

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Medy-Tox / 메디톡스 / 086900 / KRX:086900

Source: KRX statistical information